Malaria research and its influence on anti-malarial drug policy in Malawi: a case study

SOURCE: Health Research Policy and Systems
OUTPUT TYPE: Journal Article
PUBLICATION YEAR: 2016
TITLE AUTHOR(S): C.Mwendera, C.De Jager, H.Longwe, K.Phiri, C.Hongoro, C.M.Mutero
KEYWORDS: DRUG USE, MALARIA, MALAWI, POLICY IMPLEMENTATION
Print: HSRC Library: shelf number 9244
HANDLE: 20.500.11910/10288
URI: http://hdl.handle.net/20.500.11910/10288

Download this report

If you would like to obtain a copy of this Research Output, please contact Hanlie Baudin at researchoutputs@hsrc.ac.za.

Abstract

In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993 raised concerns about whether it had occurred timely and whether it had potentially led to early development of Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy changes were justifiable and supported by evidence.